does medicare cover any glp-1 drugs Drug Coverage CMS Extends Medicare's Short-Term Bridge

Its compounding-pathway status is unsettled: ibutamoren mesylate was nominated for inclusion on FDA's Section 503A bulk drug substances list, and the Pharmacy Compounding Advisory Committee reviewed the nomination at its October 29, 2024 meeting and voted against recommending it for the list, citing concerns about the strength of the safety and efficacy evidence

And it slows down our progress

Specifically, researchers have made comments about their observation of outcomes in research models, such as increased [darkened] pigmentation in the face, upper body, and buttock in experimental settings

*VYLEESI (bremelanotide injection) Prescribing Information.* 2019